Zosano On the Launching Pad Again
Zosano Pharma Corp (ZSAN) shares were up over 23% today following news last week that the company reached its final milestone in its long-term safety study of Qtrypta for the acute treatment of migraine disease. The stock is still well below the 6.65 high price from February 21st, but we can now expect the stock […]
Read Article